Please login to the form below

Not currently logged in
Email:
Password:

BMS/Roche deal for skin cancer drug

Bristol-Myers Squibb and Roche have entered into an agreement to research the combination of ipilimumab and vemurafenib for metastatic melanoma

Bristol-Myers Squibb (BMS) and Roche have entered into an agreement to research the combination of two drugs for the treatment of metastatic melanoma.

Under the agreement, the two companies will conduct a phase I/II study to evaluate the safety and efficacy of the combination of BMS' CTLA-4 inhibitor Yervoy (ipilimumab) and Roche's investigational oral BRAF inhibitor, vemurafenib.

Yervoy was recently approved by the US Food and Drug Adminstration (FDA) for the treatment of unresectable or metastatic melanoma.

If the initial trials are successful, the companies will conduct further development of the combination.

Both drugs have shown individual positive results in recent studies. A second phase III trial of Yervoy published in the New England Journal of Medicine showed significant improvement in overall survival for patients with metastatic melanoma who took Yervoy in combination with the chemotherapy dacarbazine compared to dacarbazine alone.

Roche also recently announced the results of a phase III trial that showed vemurafenib improved overall survival in people with a form of metastatic melanoma when compared to chemotherapy.

"We are excited to be working with Roche to evaluate the potential that together Yervoy and vemurafenib could improve outcomes for melanoma patients," said Brian Daniels, senior vice president, development and medical affairs, BMS.

6th June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics